
Loading, please wait...

Loading, please wait...

A recent clinical evaluation highlights a rare presentation of IMPDH1 rod-cone dystrophy. This study focuses on the rare p.Thr244Pro heterozygous variant. While many IMPDH1-associated conditions cause rapid vision loss, this variant shows a surprisingly stationary course. Understanding these genotype-phenotype correlations is vital for modern ophthalmology and genetic counseling.
The IMPDH1 gene regulates guanine nucleotide synthesis in the retina. Specifically, the p.Thr244Pro variant affects the interface between the catalytic and Bateman domains. This specific region mediates feedback regulation and nucleotide binding. Therefore, the mutation putatively disrupts allosteric control within the enzyme, though its clinical impact appears less severe than other mutations. Consequently, this variant demonstrates how specific genetic locations influence disease severity in IMPDH1 rod-cone dystrophy.
Researchers followed a 33-year-old female patient over four years. Structurally, her central retina remained well-preserved on SD-OCT imaging. However, she showed neuroretinal layer loss beyond the temporal vascular arcades. Functionally, the patient maintained normal visual acuity and color vision. Although multifocal ERG responses were slightly reduced, her condition remained stable throughout the study. This stability suggests that the peripheral sensitivity loss did not progress rapidly during the follow-up period.
The relatively stationary progression of the p.Thr244Pro variant is notable for clinicians. In contrast, other mutations like Asp226Asn often lead to aggressive retinal degeneration. Thus, genetic testing provides critical prognostic information for affected individuals. Additionally, this case underscores why clinicians must look beyond generic diagnoses to identify specific genetic markers. Such detailed characterization helps in managing patient expectations and planning future therapeutic interventions.
The p.Thr244Pro variant is a rare missense mutation. Unlike many other pathogenic variants in the IMPDH1 gene, it is associated with a relatively stable disease course. Patients may maintain good central vision and stable peripheral dysfunction well into their fourth decade of life.
The mutation occurs at the interface of the catalytic and regulatory Bateman domains. This area is essential for nucleotide binding and feedback regulation. The variant likely interferes with the allosteric regulation of guanine nucleotide biosynthesis in photoreceptor cells, leading to localized retinal dysfunction.
Retinal dystrophies exhibit high variable expressivity. By mapping specific variants to clinical outcomes, doctors can provide more accurate prognoses. This information helps patients plan for their future and assists researchers in developing targeted gene therapies for IMPDH1 rod-cone dystrophy.
Disclaimer: This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Barboni M et al. Disease progression in IMPDH1 gene-associated rod-cone dystrophy caused by a rare p.Thr244Pro heterozygous variant. Doc Ophthalmol. 2026 Feb 15. doi: 10.1007/s10633-026-10084-z. PMID: 41691573.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Case study of a rare p.Thr244Pro variant in IMPDH1 rod-cone dystrophy, showing a stable disease course and preserved central retina in the fourth decade of ...
6 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today